# Evaluation of Alirocumab Versus Ezetimibe on Top of Statin in Asia in High Cardiovascular Risk Patients With Hypercholesterolemia

> **NCT02715726** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 615 (actual)

## Conditions studied

- Hypercholesterolemia

## Interventions

- **DRUG:** Alirocumab
- **DRUG:** Placebo for alirocumab
- **DRUG:** ezetimibe
- **DRUG:** placebo for ezetimibe
- **DRUG:** atorvastatin
- **DRUG:** rosuvastatin
- **DRUG:** simvastatin

## Key facts

- **NCT ID:** NCT02715726
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07-27
- **Primary completion:** 2018-08-06
- **Final completion:** 2018-08-06
- **Target enrollment:** 615 (ACTUAL)
- **Last updated:** 2019-09-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02715726

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02715726, "Evaluation of Alirocumab Versus Ezetimibe on Top of Statin in Asia in High Cardiovascular Risk Patients With Hypercholesterolemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02715726. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*